Nirvana Life Sciences Inc. (CSE:NIRV.X)
Canada · Delayed Price · Currency is CAD 0.0300
0.00 (0.00%)
Aug 13, 2026, 2:39 PM EST
Nirvana Life Sciences Balance Sheet
Financials in millions CAD. Fiscal year is May - April.
Millions CAD. Fiscal year is May - Apr.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jan '26 Jan 31, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 |
Cash & Equivalents | 0 | 0 | 0 | 0.01 | 0.04 | 0.62 |
Cash & Short-Term Investments | 0 | 0 | 0 | 0.01 | 0.04 | 0.62 |
Cash Growth | 111.13% | 39.94% | -84.69% | -65.08% | -94.27% | - |
Other Receivables | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
Receivables | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.11 |
Prepaid Expenses | - | - | - | 0.04 | 0.09 | 0.04 |
Total Current Assets | 0.02 | 0.02 | 0.02 | 0.07 | 0.14 | 0.77 |
Property, Plant & Equipment | - | - | - | - | 0.34 | 0.43 |
Total Assets | 0.02 | 0.02 | 0.02 | 0.07 | 0.49 | 1.2 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jan '26 Jan 31, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 |
Accounts Payable | 0.17 | 0.25 | 0.18 | 0.17 | 0.07 | 0.01 |
Accrued Expenses | 0.33 | 1.15 | 0.94 | 0.78 | 0.57 | 0.01 |
Short-Term Debt | 0.14 | 0.1 | 0.03 | 0.06 | - | - |
Other Current Liabilities | - | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
Total Current Liabilities | 0.64 | 1.51 | 1.16 | 1.01 | 0.65 | 0.02 |
Total Liabilities | 0.73 | 1.51 | 1.16 | 1.01 | 0.65 | 0.02 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jan '26 Jan 31, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 |
Common Stock | 7.87 | 6.92 | 6.92 | 6.38 | 5.98 | 1.81 |
Retained Earnings | -9.15 | -8.98 | -8.62 | -7.75 | -6.26 | -0.61 |
Comprehensive Income & Other | 0.57 | 0.57 | 0.56 | 0.43 | 0.11 | -0.01 |
Total Common Equity | -0.7 | -1.48 | -1.13 | -0.94 | -0.16 | 1.18 |
Minority Interest | -0.01 | -0 | -0 | -0 | 0 | - |
Shareholders' Equity | -0.71 | -1.49 | -1.14 | -0.94 | -0.16 | 1.18 |
Total Liabilities & Equity | 0.02 | 0.02 | 0.02 | 0.07 | 0.49 | 1.2 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jan '26 Jan 31, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 |
Total Debt | 0.14 | 0.1 | 0.03 | 0.06 | - | - |
Net Cash (Debt) | -0.14 | -0.1 | -0.03 | -0.05 | 0.04 | 0.62 |
Net Cash Growth | - | - | - | - | -94.27% | - |
Net Cash Per Share | -0.01 | -0.02 | -0.01 | -0.01 | 0.01 | 0.18 |
Filing Date Shares Outstanding | 22.92 | 4.82 | 4.82 | 4.82 | 3.4 | 3.98 |
Total Common Shares Outstanding | 22.92 | 4.82 | 4.82 | 3.4 | 3.3 | 3.98 |
Working Capital | -0.62 | -1.49 | -1.14 | -0.94 | -0.5 | 0.75 |
Book Value Per Share | -0.03 | -0.31 | -0.23 | -0.28 | -0.05 | 0.30 |
Tangible Book Value | -0.7 | -1.48 | -1.13 | -0.94 | -0.16 | 1.18 |
Tangible Book Value Per Share | -0.03 | -0.31 | -0.23 | -0.28 | -0.05 | 0.30 |
Machinery | - | - | - | - | 0.46 | 0.46 |